Voltron Therapeutics, Inc. — Form D/A
Voltron Therapeutics, Inc. of NEW YORK, NY, a company, filed a Form D amendment with the SEC on 2023-11-09. $3.2M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2023-11-09
- Form: D/A
- Accession: 0001493152-23-040030
- Industry: Biotechnology
- Exemptions: 06b
- Amount sold: $3.2M
- Investors: 63
- Date of first sale: 2022-10-28
- Security types: equity, debt
- Revenue range: Decline to Disclose
- SEC file number: 021-464374
Issuer
- Name: Voltron Therapeutics, Inc.
- CIK: 0001835742
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2017
- Address: 12 E 49TH STREET, NEW YORK, NY, 10017
- Phone: 646-335-5923
Officers, directors & promoters (8)
| Name | Role | Location |
|---|
| James Ahern | Director | New York, NY |
| Matthew Duffy | Director | New York, NY |
| Matthew Eitner | Director | New York, NY |
| Patrick Gallagher | Director | Charlotte, NC |
| Paul Korner | Director | New York, NY |
| Anthony Zook | Director | Charlotte, NC |
| Matthew Duffy | Executive Officer | New York, NY |
| Patrick Gallagher | Executive Officer | Charlotte, NC |
Other filings by this issuer (4)
More